Mainz Biomed (MYNZ) Competitors $3.16 -0.27 (-7.87%) As of 12:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. FGEN, ALLK, INKT, BRNS, ALGS, VYNE, GBIO, DARE, CLNN, and GDTCShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include FibroGen (FGEN), Allakos (ALLK), MiNK Therapeutics (INKT), Barinthus Biotherapeutics (BRNS), Aligos Therapeutics (ALGS), VYNE Therapeutics (VYNE), Generation Bio (GBIO), Daré Bioscience (DARE), Clene (CLNN), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. FibroGen Allakos MiNK Therapeutics Barinthus Biotherapeutics Aligos Therapeutics VYNE Therapeutics Generation Bio Daré Bioscience Clene CytoMed Therapeutics Mainz Biomed (NASDAQ:MYNZ) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings. Do analysts rate MYNZ or FGEN? Mainz Biomed currently has a consensus target price of $14.00, suggesting a potential upside of 343.04%. FibroGen has a consensus target price of $10.00, suggesting a potential upside of 2,773.56%. Given FibroGen's higher possible upside, analysts plainly believe FibroGen is more favorable than Mainz Biomed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, MYNZ or FGEN? Mainz Biomed has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Does the media refer more to MYNZ or FGEN? In the previous week, Mainz Biomed had 7 more articles in the media than FibroGen. MarketBeat recorded 9 mentions for Mainz Biomed and 2 mentions for FibroGen. FibroGen's average media sentiment score of 0.94 beat Mainz Biomed's score of 0.36 indicating that FibroGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral FibroGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer MYNZ or FGEN? FibroGen received 332 more outperform votes than Mainz Biomed when rated by MarketBeat users. However, 73.68% of users gave Mainz Biomed an outperform vote while only 59.04% of users gave FibroGen an outperform vote. CompanyUnderperformOutperformMainz BiomedOutperform Votes1473.68% Underperform Votes526.32% FibroGenOutperform Votes34659.04% Underperform Votes24040.96% Do insiders and institutionals hold more shares of MYNZ or FGEN? 72.7% of FibroGen shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 2.0% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation and earnings, MYNZ or FGEN? Mainz Biomed has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMainz Biomed$893.99K8.20-$26.30M-$65.60-0.05FibroGen$29.62M1.19-$284.23M-$0.48-0.73 Is MYNZ or FGEN more profitable? Mainz Biomed has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. Company Net Margins Return on Equity Return on Assets Mainz BiomedN/A N/A N/A FibroGen -67.66%N/A -36.17% SummaryMainz Biomed beats FibroGen on 8 of the 15 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.27M$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-0.057.3622.6118.58Price / Sales8.20241.71397.51103.15Price / CashN/A65.8538.1834.62Price / Book0.296.486.704.26Net Income-$26.30M$143.43M$3.22B$248.31M7 Day Performance-1.25%1.69%1.26%1.34%1 Month Performance7.85%6.58%3.73%3.92%1 Year Performance-89.74%-2.63%15.82%5.33% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.9792 of 5 stars$3.16-7.9%$14.00+343.0%-90.3%$7.27M$893,991.00-0.0530Short Interest ↓Gap UpFGENFibroGen4.6296 of 5 stars$0.29+1.3%$10.00+3,348.3%-69.8%$29.27M$29.62M-0.24570Upcoming EarningsAnalyst ForecastALLKAllakos4.5992 of 5 stars$0.32-0.6%$2.00+517.5%-69.0%$29.22MN/A-0.16190Upcoming EarningsShort Interest ↓Positive NewsINKTMiNK Therapeutics2.7631 of 5 stars$7.26+0.1%$37.50+416.5%-23.5%$28.79MN/A-1.8630Positive NewsGap UpBRNSBarinthus Biotherapeutics2.3512 of 5 stars$0.71-2.7%$5.17+627.7%-45.4%$28.64M$14.97M-0.48107Short Interest ↑ALGSAligos Therapeutics3.8955 of 5 stars$4.52-3.4%$70.00+1,448.7%-70.8%$27.64M$3.95M-0.3490Upcoming EarningsGap UpVYNEVYNE Therapeutics2.4763 of 5 stars$1.80-2.7%$6.88+281.9%-47.2%$27.38M$501,000.00-2.0930Upcoming EarningsShort Interest ↑GBIOGeneration Bio3.5871 of 5 stars$0.40+2.6%$7.33+1,723.3%-84.7%$26.95M$19.89M-0.18150Positive NewsDAREDaré Bioscience2.2856 of 5 stars$2.95+1.7%$24.00+713.6%-20.1%$26.11M$9,784.00-4.9930Short Interest ↓CLNNClene2.8295 of 5 stars$2.91-3.0%$55.25+1,798.6%-65.6%$25.01M$342,000.00-0.55100Upcoming EarningsGDTCCytoMed Therapeutics2.1502 of 5 stars$2.28-7.3%$5.00+119.3%+12.3%$24.94MN/A0.00N/AGap Down Related Companies and Tools Related Companies FibroGen Alternatives Allakos Alternatives MiNK Therapeutics Alternatives Barinthus Biotherapeutics Alternatives Aligos Therapeutics Alternatives VYNE Therapeutics Alternatives Generation Bio Alternatives Daré Bioscience Alternatives Clene Alternatives CytoMed Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MYNZ Stock Free MYNZ Stock Alerts